|
Jul 16
|
Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development
|
|
Jul 2
|
Oragenics Completes Approximately $16.5 Million Offering
|
|
Jul 1
|
Top Midday Decliners
|
|
Jul 1
|
Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants
|
|
Jun 10
|
Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium
|
|
May 28
|
Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split
|
|
May 13
|
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia
|
|
May 12
|
Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision
|
|
Apr 9
|
Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial
|
|
Apr 7
|
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit
|
|
Feb 24
|
Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health
|
|
Feb 11
|
Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment
|
|
Jun 27
|
Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
|
|
Jun 26
|
Oragenics, Inc. Announces Closing of Public Offering
|
|
Jun 25
|
Oragenics, Inc. Announces Pricing of Public Offering
|
|
Jun 24
|
Oragenics, Inc. Announces Proposed Public Offering
|
|
May 22
|
Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer
|
|
Mar 1
|
Oragenics Announces Closing of Public Offering
|
|
Feb 28
|
Oragenics Announces Pricing of Public Offering
|
|
Feb 27
|
Oragenics Announces Proposed Public Offering
|